ST-segment analysis in ambulatory ECG (AECG or Holter) monitoring in patients with coronary artery disease: Clinical significance and analytic techniques

Annals of Noninvasive Electrocardiology

Volumn 10, Issue 2, 2005, Pages 263-278

  Stone, Peter H ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; NIFEDIPINE; NITRATE; PROPRANOLOL; VERAPAMIL;

AMBULATORY MONITORING; CORONARY ARTERY DISEASE; HEART MUSCLE ISCHEMIA; HOLTER MONITORING; HUMAN; METHODOLOGY; PRIORITY JOURNAL; REVIEW; SOLID STATE; ST SEGMENT; ST SEGMENT DEPRESSION; STATISTICAL SIGNIFICANCE;

ADRENERGIC BETA-ANTAGONISTS; AMLODIPINE; ANTILIPEMIC AGENTS; CARDIOVASCULAR AGENTS; CORONARY ARTERIOSCLEROSIS; DILTIAZEM; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY, AMBULATORY; HUMANS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; SIGNAL PROCESSING, COMPUTER-ASSISTED; TREATMENT OUTCOME;

EID: 18444398339     PISSN: 1082720X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1542-474X.2005.10203.x     Document Type: Review

References (58)

1. Stern S, Tzivoni D. Early detection of silent ischaemic heart disease by 24-hour electrocardiographic monitoring of active subjects. Br Heart J 1974;36:481-486.
2. Stone PH, Chaitman BR, McMahon RP, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) Study. Relationship between exercise-induced and ambulatory ischemia in patients with stable coronary disease. Circulation 1996;94:1537-1544.
3. Chipkin SR, Frid D, Alpert JS, et al. Frequency of painless myocardial ischemia during exercise tolerance testing in patients with and without diabetes mellitus. Am J Cardiol 1987;59:61-65.
4. Marchant B, Umachandran V, Stevenson R, et al. Silent myocardial ischemia: Role of subclinical neuropathy in patients with and without diabetes. J Am Coll Cardiol 1993;22:1433-1437.
5. Rosen SD, Paulesu E, Nihoyannopoulos P, et al. Silent ischemia as a central problem: Regional brain activation compared in silent and painful myocardial ischemia. Ann Intern Med 1996;124:939-949.
6. Deanfield JE, Maseri A, Selwyn AP, et al. Myocardial ischaemia during daily life in patients with stable angina: Its relation to symptoms and heart rate changes. Lancet 1983;2:753-758.
7. Chierchia S, Gallino A, Smith G, et al. Role of heart rate in pathophysiology of chronic stable angina. Lancet 1984;2:1353-1357.
8. Nabel EG, Barry J, Rocco MB, et al. Variability of transient myocardial ischemia in ambulatory patients with coronary artery disease. Circulation 1988;78:60-67.
9. Deanfield JE, Shea M, Kensett M, et al. Silent myocardial ischaemia due to mental stress. Lancet 1984;2:1001-1005.
10. Yeung AC, Vekshtein VI, Krantz DS, et al. The effect of atherosclerosis on the vasomotor response of coronary arteries to mental stress. N Engl J Med 1991;325:1551-1556.
11. Verrier RL, Hagestad EL, Lown B. Delayed myocardial ischemia induced by anger. Circulation 1987;75:249-254.
12. Gordon JB, Ganz P, Nabel EG, et al. Atherosclerosis influences the vasomotor response of epicardial coronary arteries to exercise. J Clin Invest 1989;83:1946-1952.
13. Maouad J, Fernandez F, Barrillon A, et al. Diffuse or segmental narrowing (spasm) of the coronary arteries during smoking demonstrated on angiography. Am J Cardiol 1984;53:354-355.
14. Nabel EG, Ganz P, Gordon JB, et al. Dilation of normal and constriction of atherosclerotic coronary arteries caused by the cold presser test. Circulation 1988;77:43-52.
15. Andrews TC, Fenton T, Toyosaki N, et al. Subsets of ambulatory myocardial ischemia based on heart rate activity. Circadian distribution and response to anti-ischemic medication. The Angina and Silent Ischemia Study Group (ASIS). Circulation 1993;88:92-100.
16. Sharaf B, Williams DO, Miele NJ, et al. A detailed angiographic analysis of patients with ambulatory electrocardiographic ischemia: Results from the Asymptomatic Cardiac Ischemia Pilot (ACIP) Study Angiographic Core Laboratory. J Am Coll Cardiol 1997;29:78-84.
17. Carbajal EV, Deedwania PC. Beta-blocking therapy for silent myocardialischemia. In Dunitz M (ed.): Silent Myocardial Ischemia, 1998: pp. 111-125.
18. Pratt C, McMahon RP, Goldstein S, et al. Comparison of subgroups assigned to medical regimens used to suppress cardiac ischemia (the Asymptomatic Cardiac Ischemia Pilot {ACIP} study). Am J Cardiol 1996;77:1302-1309.
19. Parmley WW, Nesto RW, Singh BN, et al. Attenuation of the circadian patterns of myocardial ischemia with nifedipine GITS in patients with chronic stable angina. N-CAP Study Group. J Am Coll Cardiol 1992;19:1380-1389.
20. von Arnim T. Medical treatment to reduce total ischemic burden: Total Ischemic Burden Bisoprolol Study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. The TIBBS Investigators. J Am Coll Cardiol 1995;25:231-238.
21. Deanfield JE, Detry JM, Lichtlen PR, et al. Amlodipine reduces transient myocardial ischemia in patients with coronary artery disease: Double-blind Circadian Anti-Ischemia Program in Europe (CAPE Trial). J Am Coll Cardiol 1994;24:1460-1467.
22. Davies RF, Habibi H, Klinke WP, et al. Effect of amlodipine, atenolol and their combination on myocardial ischemia during treadmill exercise and ambulatory monitoring. Canadian Amlodipine/Atenolol in Silent Ischemia Study (CASIS) Investigators. J Am Coll Cardiol 1995;25:619-625.
23. Deanfield JE, Detry JM, Sellier P, et al. Medical treatment of myocardial ischemia in coronary artery disease: Effect of drug regime and irregular dosing in the CAPE II trial. J Am Coll Cardiol 2002;40:917-925.
24. von Arnim T, Erath A. Nitrates and calcium antagonists for silent myocardial ischemia. Am J Cardiol 1988;61:15E-18E.
25. Nabel EG, Barry J, Rocco MB, et al. Effects of dosing intervals on the development of tolerance to high dose transdermal nitroglycerin. Am J Cardiol 1989;63:663-669.
26. Sharaf BL, Williams DO, Miele NJ, et al. A detailed angiographic analysis of patients with ambulatory electrocardiographic ischemia: Results from the Asymptomatic Cardiac Ischemia Pilot (ACIP) Study Angiographic Core Laboratory. J Am Coll Cardiol 1997;29:78-84.
27. Andrews TC, Raby K, Barry J, et al. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 1997;95:324-328.
28. van Boven AJ, Jukema JW, Zwinderman AH, et al. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group. Circulation 1996;94:1503-1505.
29. Stone PH, Lloyd-Jones DM, Kinlay S, et al. The effect of intensive lipid-lowering, with or without antioxidant vitamins, vs moderate lipid-lowering, on myocardial ischemia in patients with stable coronary artery disease: The Vascular Basis for the Treatment of Myocardial Ischemia Study. Circulation 2005; in press.
30. Pepine CJ, Rouleau JL, Annis K, et al. Effects of angiotensin-converting enzyme inhibition on transient ischemia: The Quinapril Anti-ischemia and Symptoms of Angina Reduction (QUASAR) Trial. J Am Coll Cardiol 2003;42:2049-2059.
31. Von Arnim T. Prognostic significance of transient ischemic episodes: Response to treatment shows improved prognosis. Results of the Total Ischemic Burden Bisoprolol Study (TIBBs) follow-up. J Am Coll Cardiol 1996;28:20-24.
32. Deedwania PC, Carbajal EV. Usefulness of ambulatory silent myocardial ischemia added to the prognostic value of exercise test parameters in predicting risk of cardiac death in patients with stable angina pectoris and exercise-induced myocardial ischemia. Am J Cardiol 1991;68:1279-1286.
33. Madjlessi-Simon T, Mary-Krause M, Fillette F, et al. Persistent transient myocardial ischemia despite beta-adrenergic blockade predicts a higher risk of adverse cardiac events in patients with coronary artery disease. J Am Coll Cardiol 1996;27:1586-1591.
34. Pepine CJ, Cohn PF, Deedwania PC, et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST). Circulation 1994;90:762-768.
35. Dargie HJ, Ford I, Fox KM. Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group. Eur Heart J 1996;17:104-112.
36. Rogers W, Bourassa MG, Andrews T, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) Study: Outcome at 1 year for patients with asymptomatic cardiac ischemia randomized to medical therapy or revascularization. J Am Coll Cardiol 1995;26:594-605.
37. Davies RF, Goldberg AD, Forman S, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) Study two-year follow-up: Outcomes of patients randomized to initial strategies of medical therapy versus revascularization. Circulation 1997;95:2037-2043.
38. Stone PH, Chaitman BR, Forman S, et al. Prognostic significance of myocardial ischemia detected by ambulatory electrocardiography, exercise treadmill testing, and electrocardiogram at rest to predict cardiac events by one year (the Asymptomatic Cardiac Ischemia Pilot [ACIP] Study). Am J Cardiol 1997;80:1395-1401.
39. Patel DJ, Gomma AH, Knight CJ, et al. Why is recurrent myocardial ischaemia a predictor of adverse outcome in unstable angina? An observational study of myocardial ischaemia and its relation to coronary anatomy. Eur Heart J 2001;22:1991-1996.
40. Zairis MN, Ambrose JA, Papadaki OA, et al. C-reactive protein and ST-segment monitoring by continuous 12-lead electrocardiogram in patients with primary unstable angina pectoris. Am J Cardiol 2003;91:600-603.
41. Gottlieb SO, Weisfeldt ML, Ouyang P, et al. Silent ischemia as a marker for early unfavorable outcomes in patients with unstable angina. N Engl J Med 1986;314:1214-1219.
42. Lanza GA, Pedrotti P, Rebuzzi AG, et al. Usefulness of the addition of heart rate variability to Holter monitoring in predicting in-hospital cardiac events in patients with unstable angina pectoris. Am J Cardiol 1997;80:263-267.
43. Langer A, Singh N, Freeman MR, et al. Detection of silent ischemia adds to the prognostic value of coronary anatomy and left ventricular function in predicting outcome in unstable angina patients. Can J Cardiol 1995;11:117-122.
44. Patel DJ, Knight CJ, Holdright DR, et al. Pathophysiology of transient myocardial ischemia in acute coronary syndromes. Characterization by continuous ST-segment monitoring. Circulation 1997;95:1185-1192.
45. Stone P, Thompson B, Zaret BL, et al. Factors associated with failure of medical therapy in patients with unstable angina and non-Q-wave MI: A TIMI-IIIB Database Study. European Heart 1999;20:1084-1093.
46. Akkerhuis KM, Klootwijk PA, Lindeboom W, et al. Recurrent ischaemia during continuous multilead ST-segment monitoring identifies patients with acute coronary syndromes at high risk of adverse cardiac events; meta-analysis of three studies involving 995 patients. Eur Heart J 2001;22:1997-2006.
47. Klootwijk P, Meij S, Melkert R, et al. Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE). Circulation 1998;98:1358-1364.
48. Correia LC, Magalhaes LP, Santana O, et al. Effect of atorvastatin (80 mg) on recurrent ischemia in unstable angina pectoris or non-ST-elevation acute myocardial infarction. Am J Cardiol 2003;91:1355-1357.
49. Schulman SP, Thiemann DR, Ouyang P, et al. Effects of acute hormone therapy on recurrent ischemia in postmenopausal women with unstable angina. J Am Coll Cardiol 2002;39:231-237.
50. Gill JB, Cairns JA, Roberts RS, et al. Prognostic importance of myocardial ischemia detected by ambulatory monitoring early after acute myocardial infarction. N Engl J Med 1996;334:65-70.
51. Krucoff MW, Croll MA, Pope JE, et al. Continuous 12-lead ST-segment recovery analysis in the TAMI 7 study. Performance of a noninvasive method for real-time detection of failed myocardial reperfusion. Circulation 1993;88:437-446.
52. de Lemos JA, Braunwald E. ST segment resolution as a tool for assessing the efficacy of reperfusion therapy. J Am Coll Cardiol 2001;38:1283-1294.
53. Roe MT, Green CL, Giugliano RP, et al. Improved speed and stability of ST-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute ST-segment elevation myocardial infarction. J Am Coll Cardiol 2004;43:549-556.
54. Crawford MH, Bernstein SJ, Deedwania PC, et al. ACC/AHA Guidelines for Ambulatory Electrocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the Guidelines for Ambulatory Electrocardiography). Developed in collaboration with the North American Society for Pacing and Electrophysiology. J Am Coll Cardiol 1999;34:912-948.
55. Lanza GA, Mascellanti M, Placentino M, et al. Usefulness of a third Holter lead for detection of myocardial ischemia. Am J Cardiol 1994;74:1216-1219.
56. Seeberger MD, Moerlen J, Skarvan K, et al. The inverse Nehb J lead increases the sensitivity of Holter electrocardiographic monitoring for detecting myocardial ischemia. Am J Cardiol 1997;80:1-5.
57. Stone PH, MacCallum G. ST segment analysis in ambulatory ECG (Holter) monitoring: Clinical significance and analytic techniques. In Zareba W, Maison-Blanche P, Locati EH (eds.): Noninvasive Electrocardiology in Clinical Practice. Armonk, NY: Futura Publishing Company, 2001:257-304.
58. Bjerregaard P, El-Shafei A, Kotar SL, et al. ST segment analysis by Holter Monitoring: Methodological considerations. Ann Noninvasive Electrocardiol 2003;8:200-207.